NCT04409795View on ClinicalTrials.gov

Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 26, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Type 1 DiabetesMonogenic Diabetes
Interventions
DRUG

Metformin Extended Release Oral Tablet

Initial oral hypoglycemic agent added to existing insulin treatment

DRUG

Sitagliptin

Secondary oral hypoglycemic agent added to existing insulin treatment (for those who are intolerant to or unable to achieve glycemic targets with metformin)

Trial Locations (1)

02215

Joslin Diabetes Center, Boston

All Listed Sponsors
lead

Joslin Diabetes Center

OTHER

NCT04409795 - Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study | Biotech Hunter | Biotech Hunter